Brain lipid composition in postnatal iron-induced motor behavior alterations following chronic neuroleptic administration in mice.
Several studies have shown that deficient uptake or excessive break down of membrane phospholipids may be associated with neurodegenerative and psychiatric disorders. The purpose of the present study was to examine the effects of postnatal iron administration in lipid composition and behavior and whether or not the established effects may be altered by subchronic administration of the neuroleptic compounds, clozapine and haloperidol. In addition to motor activities such as locomotion, rearing and activity, a targeted lipidomics approach has been used to investigated the brains of eight groups of mice (four vehicle groups and four iron groups) containing six individuals in each group treated with vehicle, low dose clozapine, high dose clozapine and haloperidol. Lipids were extracted by the Folch method and analyzed using reversed-phase capillary liquid chromatography coupled on-line to electrospray ionization mass spectrometry (LC/ESI/MS). Identification of phosphatidylcholine (PC) and sphingomyelin (SM) molecular species was based on their retention time, m/z ratio, head group specific up-front fragmentation and analysis of the product ions produced upon fragmentation. A comparison between the Ve-groups and Fe-groups showed that levels of PC and SM molecular species and motor activities were significantly lower in Fe-Ve compared to Ve-Ve. The effects of neuroleptic treatment with and without iron supplementation were studied. In conclusion our results support the hypothesis that an association between psychiatric disorders and lipid and behavior abnormalities in the brain exists.
Isaac
Giorgis
G
Department of Analytical Chemistry, Biomedical Center, Uppsala University, Sweden.
Fredriksson
Anders
A
Danielsson
Rolf
R
Eriksson
Per
P
Bergquist
Jonas
J
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D001923:Brain Chemistry / Q000187:drug effects*; D003024:Clozapine / Q000494:pharmacology; D019587:Dietary Supplements; D004334:Drug Administration Schedule; D005260:Female; D006220:Haloperidol / Q000494:pharmacology; D007501:Iron / Q000494:pharmacology*; D008563:Membrane Lipids / Q000737:chemistry*; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects*; D010713:Phosphatidylcholines / Q000737:chemistry; D011247:Pregnancy; D013109:Sphingomyelins / Q000737:chemistry
D014150:Antipsychotic Agents; D008563:Membrane Lipids; D010713:Phosphatidylcholines; D013109:Sphingomyelins; D007501:Iron; D003024:Clozapine; D006220:Haloperidol